Harmony Biosciences Reports Third Quarter 2020 Financial Results and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Harmony Biosciences (HRMY) Misses Q3 EPS by 9c, Revenues Beat
November 12, 2020 8:03 AM ESTHarmony Biosciences (NASDAQ: HRMY) reported Q3 EPS of ($0.14), $0.09 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $45.6 million versus the consensus estimate of $40.07 million.
Third Quarter 2020 Financial Highlights:
Net product revenue was $45.6 million for the third quarter ended September 30, 2020.Research and development expenses were $4.2 million for the third quarter of 2020 compared with $4.3 million for the third quarter of 2019.Sales and marketing expenses were $12.6 million for the third quarter of 2020 compared with $12.9 million for the third... More